Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 35, Issue 6, Pages 607–613
http://dx.doi.org/10.1155/2013/735843
Research Article

Is Human Papillomavirus Associated with Prostate Cancer Survival?

1Oncology Institute of Southern Switzerland (IOSI), Ospedale San Giovanni, 6500 Bellinzona, Switzerland
2Department of Medical Sciences, University of Trieste, Cattinara Hospital, I-34149 Trieste, Italy

Received 24 June 2013; Revised 10 September 2013; Accepted 7 October 2013

Academic Editor: Ahmed O. Kaseb

Copyright © 2013 Mariarosa Pascale et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. zur Hausen, “Human papillomaviruses and their possible role in squamous cell carcinomas,” Current Topics in Microbiology and Immunology, vol. 78, pp. 1–30, 1977. View at Google Scholar · View at Scopus
  2. M. Dürst, L. Gissmann, H. Ikenberg, and H. zur Hausen, “A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions,” Proceedings of the National Academy of Sciences of the United States of America, vol. 80, no. 12 I, pp. 3812–3815, 1983. View at Google Scholar · View at Scopus
  3. M. Boshart, L. Gissmann, H. Ikenberg, A. Kleinheinz, W. Scheurlen, and H. zur Hausen, “A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer,” The EMBO Journal, vol. 3, no. 5, pp. 1151–1157, 1984. View at Google Scholar · View at Scopus
  4. E. M. de Villiers, C. Fauquet, T. R. Broker, H. U. Bernard, and H. zur Hausen, “Classification of papillomaviruses,” Virology, vol. 324, no. 1, pp. 17–27, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. H. U. Bernard, R. D. Burk, Z. Chen, K. van Doorslaer, H. Z. Hausen, and E. M. de Villiers, “Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments,” Virology, vol. 401, no. 1, pp. 70–79, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, “Human papillomaviruses,” in IARC Monographs on the Evaluation of Carcinogenic Risks To Humans. A Review of Human Carcinogens, International Agency for Research on Cancer, Ed., vol. 100, part B of Biological Agents, pp. 255–314, WHO, Geneva, Switzerland, 2012. View at Google Scholar
  7. M. L. Gillison, W. M. Koch, R. B. Capone et al., “Evidence for a causal association between human papillomavirus and a subset of head and neck cancers,” Journal of the National Cancer Institute, vol. 92, no. 9, pp. 709–720, 2000. View at Google Scholar · View at Scopus
  8. A. Argiris, M. V. Karamouzis, D. Raben, and R. L. Ferris, “Head and neck cancer,” The Lancet, vol. 371, no. 9625, pp. 1695–1709, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. C. A. Moody and L. A. Laimins, “Human papillomavirus oncoproteins: pathways to transformation,” Nature Reviews Cancer, vol. 10, no. 8, pp. 550–560, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. M. E. McLaughlin-Drubin, J. Meyers, and K. Munger, “Cancer associated human papillomaviruses,” Current Opinion in Virology, vol. 2, pp. 459–466, 2012. View at Google Scholar
  11. O. López-Ocejo, A. Viloria-Petit, M. Bequet-Romero, D. Mukhopadhyay, J. Rak, and R. S. Kerbel, “Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner,” Oncogene, vol. 19, no. 40, pp. 4611–4620, 2000. View at Google Scholar · View at Scopus
  12. L. Xi, S. Wang, C. Wang et al., “The pro-angiogenic factors stimulated by human papillomavirus type 16 E6 and E7 protein in C33A and human fibroblasts,” Oncology Reports, vol. 21, no. 1, pp. 25–31, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. B. M. El Sabaa, M. Meleiss, and I. Zaki, “EGF expression and microvascular density in relation to highrisk-HPV infection in cervical carcinoma—an immunohistochemical study,” The American Journal of Medicine, vol. 48, pp. 47–57, 2012. View at Google Scholar
  14. H. O. Adami, H. Kuper, S. O. Andersson, R. Bergström, and J. Dillner, “Prostate cancer risk and serologic evidence of human papilloma virus infection: a population-based case-control study,” Cancer Epidemiology Biomarkers and Prevention, vol. 12, no. 9, pp. 872–875, 2003. View at Google Scholar · View at Scopus
  15. G. J. Leiros, S. R. Galliano, M. E. Sember, T. Kahn, E. Schwarz, and K. Eiguchi, “Detection of human papillomavirus DNA and p53 codon 72 polymorphism in prostate carcinomas of patients from Argentina,” BMC Urology, vol. 5, article 15, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. M. L. Martinez-Fierro, R. J. Leach, L. S. Gomez-Guerra et al., “Identification of viral infections in the prostate and evaluation of their association with cancer,” BMC Cancer, vol. 10, article 326, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. Y. Lin, Q. Mao, X. Zheng et al., “Human papillomavirus 16 or 18 infection and prostate cancer risk: a meta-analysis,” Irish Journal of Medical Science, vol. 180, no. 2, pp. 497–503, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Sutcliffe, R. P. Viscidi, C. Till et al., “Human papillomavirus types 16, 18, and 31 serostatus and prostate cancer risk in the prostate cancer prevention trial,” Cancer Epidemiology Biomarkers and Prevention, vol. 19, no. 2, pp. 614–618, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Aghakhani, R. Hamkar, M. Parvin et al., “The role of human papillomavirus infection in prostate carcinoma,” Scandinavian Journal of Infectious Diseases, vol. 43, no. 1, pp. 64–69, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. A. C. Chen, T. Waterboer, A. Keleher et al., “Human papillomavirus in benign prostatic hyperplasia and prostatic adenocarcinoma patients,” Pathology and Oncology Research, vol. 17, no. 3, pp. 613–617, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. H. C. T. Groom, A. Y. Warren, D. E. Neal, and K. N. Bishop, “No evidence for infection of UK prostate cancer patients with XMRV, BK virus, trichomonas vaginalis or human papilloma viruses,” PLoS ONE, vol. 7, no. 3, Article ID e34221, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. J. Hrbacek, M. Urban, E. Hamsikova et al., “Serum antibodies against genitourinary infectious agents in prostate cancer and benign prostate hyperplasia patients: a case-control study,” BMC Cancer, vol. 11, article 53, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Rogler, M. Rogenhofer, A. Borchardt et al., “P53 codon 72 (Arg72Pro) polymorphism and prostate cancer risk: association between disease onset and proline genotype,” Pathobiology, vol. 78, no. 4, pp. 193–200, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. R. Tachezy, J. Hrbacek, J. Heracek et al., “HPV persistence and its oncogenic role in prostate tumors,” Journal of Medical Virology, vol. 84, pp. 1636–1645, 2012. View at Google Scholar
  25. V. Faoro and A. Sapino, “Tissue microarray (TMA),” in Guidelines for Molecular Analysis in Archive Tissues, G. Stanta, Ed., pp. 23–26, Springer, Berlin, Germany, 2011. View at Google Scholar
  26. N. S. Goldstein, S. M. Hewitt, C. R. Taylor et al., “Recommendations for improved standardization of immunohistochemistry,” Applied Immunohistochemistry & Molecular Morphology, vol. 15, no. 2, pp. 124–133, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. V. Faoro, R. Barbazza, S. Bonin, D. Brunetti, S. Sulfaro, and G. Stanta, “Detection of HPV E7 oncoviral protein in cervical lesions by a new antibody,” Applied Immunohistochemistry & Molecular Morphology, vol. 21, pp. 341–350, 2013. View at Google Scholar
  28. P. Pauluzzi, S. Bonin, M. A. Gonzalez Inchaurraga, G. Stanta, and G. Trevisan, “Detection of spirochaetal DNA simultaneously in skin biopsies, peripheral blood and urine from patients with erythema migrans,” Acta Dermato-Venereologica, vol. 84, no. 2, pp. 106–110, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. J. J. M. van Dongen, A. W. Langerak, M. Brüggemann et al., “Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 concerted action BMH4-CT98-3936,” Leukemia, vol. 17, no. 12, pp. 2257–2317, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. I. Petersen, C. Schewe, K. Schlüns et al., “Inter-laboratory validation of PCR-based HPV detection in pathology specimens,” Virchows Archiv, vol. 451, no. 3, pp. 701–716, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. G. Basili, S. Bonin, and I. Dotti, “DNA sequencing from PCR products,” in Guidelines for Molecular Analysis in Archive Tissues, G. Stanta, Ed., pp. 135–141, Springer, Berlin, Germany, 2011. View at Google Scholar
  32. K. Biedermann, N. Dandachi, M. Trattner et al., “Comparison of real-time PCR signal-amplified in situ hybridization and conventional PCR for detection and quantification of human papillomavirus in archival cervical cancer tissue,” Journal of Clinical Microbiology, vol. 42, no. 8, pp. 3758–3765, 2004. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Steinau, S. S. Patel, and E. R. Unger, “Efficient DNA extraction for HPV genotyping in formalin-fixed, paraffin-embedded tissues,” Journal of Molecular Diagnostics, vol. 13, no. 4, pp. 377–381, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. N. J. Whitaker, W. K. Glenn, A. Sahrudin, M. M. Orde, W. Delprado, and J. S. Lawson, “Human papillomavirus and Epstein Barr virus in prostate cancer: koilocytes indicate potential oncogenic influences of human papillomavirus in prostate cancer,” Prostate, vol. 73, pp. 236–241, 2013. View at Google Scholar
  35. S. de Sanjose, W. G. Quint, L. Alemany et al., “Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study,” The Lancet Oncology, vol. 11, pp. 1048–1056, 2010. View at Google Scholar
  36. S. K. Tewari, M. Sill, J. H. Long et al., “Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the gynecologic oncology group,” Journal of Clinical Oncology, vol. 31, supplement, 2013, abstract no. 3. View at Google Scholar